Search   |     Toll free: +1-800-447-9407   |     support@s2mtrainings.com

AI and the EU AI Act for Medical Devices

Instructor John E Lincoln
Webinar ID 96434
14 Days Left To REGISTER

Date Wednesday, July 29, 2026
Time 10:00 AM PDT | 01:00 PM EDT
Duration 90 Minutes  

Webinar Price Details

Overview

The Artificial Intelligence Act  establishes a regulatory and legal framework for AI within the EU. It covers most AI systems, with exemptions for AI used only for military, national security, research purposes, or for non-professional use. The Act classifies AI applications by their risk of causing harm.

There are four levels - unacceptable, high, limited, minimal - plus an additional category for general-purpose AI. Applications with unacceptable risks are banned. High-risk applications must comply with security, transparency and quality obligations, and undergo conformity assessments by a Notified Body. Limited-risk applications only have transparency obligations. Minimal-risk applications are not regulated. For general-purpose AI, transparency requirements are imposed, with reduced requirements for open source models, and additional evaluations for high-capability, higher risk models. They must be evaluated both before they are placed on the market and throughout their life cycle. The list of high-risk applications can be expanded over time without modifying the AI Act itself.The risk-based scheme asssigns regulatory duties to providers and deployers of AI systems. These duties become more demanding as the impact on health, safety, or fundamental rights increases.

This  ensures that the focus is on systems with significant risks while allowing lighter approaches for lower risks. For providers of general-purpose AI models: They must publish a summary of the training data, adopt a policy to comply with copyright law, and provide technical documentation to downstream providers and supervisory authorities. Models designated as posing systemic risk must also carry out model evaluations and adversarial testing, assess and mitigate risks such as bias and security failures, report serious incidents, and ensure an adequate level of cybersecurity.

Why should you Attend

This webinar will cover the EU'S approach to unified AI governance throughout the member states of the EU for all AI enabled products and systems. This webinar will focus on the medical device segmanet of those products and systems and manufacturer's roles and responsebilities in the adherence to them. These requirements apply to all manufacturere marketing and selling into the EU market, regarless of where the devices are actually manufactured. AI is a fast evolving family of technologies that contributes to a wide array of economic, environmental and societal benefits across the entire spectrum of industries and social activities.

By improving prediction, optimising operations and resource allocation, and personalising digital solutions available for individuals and organisations, the use of AI can provide key competitive advantages to undertakings and support socially and environmentally beneficial outcomes, e.g., in healthcare. On the other hand, AI may generate risks and cause harm to public interests and fundamental rights that are protected by Union law. Such harm might be material or immaterial, including physical, psychological, societal or economic harm. These new requirements are designed to address both. The ultimate goal: AI should be a human-centric technology. It should serve as a tool for people, with the ultimate aim of increasing human well-being.

Areas Covered in the Session

  • The EU AI Act of 2024, with focus on Medical Devices
  • A Risk-Based Approach 
  • Key Points
  • Enforcement
  • The Notified Body's Role
  • Basic Documentation Requirements

Who Will Benefit

  • Senior management in Devices, AI Technology 
  • Marketing
  • QA
  • RA
  • R&D
  • Engineering
  • Production
  • Operations
  • Consultants; others tasked with AI product projects

Speaker Profile

John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide.

John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.